# Foundation for a Better World

> Foundation for a Better World is a VC fund backing Health Care. See 5 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Total investments: 5
- Last investment: Nov 2025
- Lead investor: 0%
- Last updated: Aug 2026
- Website: https://forabetterworldfoundation.org/

Foundation for a Better World is a VC fund focused on Health Care and Neuroscience. The Foundation For A Better World is a not-for-profit organization that seeks to support medical research, quality education, and global development with a focus on achieving measurable results through charitable donations.

## Contacts

5 contacts available for Foundation for a Better World. Shizune tracks 1 team members at Foundation for a Better World. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/foundation-for-a-better-world?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 40% |
| Neuroscience | 2 | 40% |
| Biotechnology | 2 | 40% |
| Pharmaceutical | 2 | 40% |
| Medical | 1 | 20% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 40% |
| Seed | 1 | 20% |
| Series B | 1 | 20% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Adam Hoffman | Executive | 1 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| MindImmune Therapeutics | MindImmune Therapeutics is a pharmaceutical company developing first-in-class drugs that target the immune system to treat diseases of the central nervous system, including Alzheimer’s and Huntington’s disease, pain, and psychiatric disorders. It is increasingly clear that the central nervous system and the immune system are intimately integrated.Consequently, immune system dysfunction is a critical, often causative, factor in brain dysfunction. MindImmune scientists are at the forefront in recognizing the therapeutic opportunities in targeting the immune system to treat brain disease. MindImmune is based in Kingston, RI and is building an affiliation with the George & Anne Ryan Institute for Neuroscience at the University of Rhode Island to leverage the rapidly expanding Rhode Island ecosystem of academic neurosciences resources to advance its drug development programs. | $15.2M | Series A | Nov 24, 2025 |  |
| Therini Bio | Therini Bio is dedicated to the research and development of novel therapeutics for the treatment of neurological diseases. The company's approach is based on novel findings by the Akassoglou lab at Gladstone/UCSF that implicate fibrin as a key driver of neuroinflammation. | $39M | Series A | May 14, 2025 |  |
| Neuro Therapia | NeuroTherpia, Inc., founded in 2015 by Drs. Mohamed Naguib and Joseph Foss, is developing new therapies for diseases with an underlying component of neuroinflammation. Initial research has led to the development of our lead compound NTRX-07. NTRX-07 (previously known as MDA7) has been shown to decrease activation of microglial cells in the brain.Decreasing activation of these cells leads to decreased inflammation and decreased injury to surrounding nerve cells. Decreasing this inflammation can treat and even prevent the development of neuropathic pain in settings of nerve injury or chemotherapy. Recent work has shown that blocking this inflammation is also important in reversing the effects seen in Alzheimer's disease. We are currently doing preclinical safety studies and plan on studying NTRX-07 in humans in 2016. | $12.3M | Series B | Aug 06, 2024 |  |
| Therini Bio | Therini Bio is dedicated to the research and development of novel therapeutics for the treatment of neurological diseases. The company's approach is based on novel findings by the Akassoglou lab at Gladstone/UCSF that implicate fibrin as a key driver of neuroinflammation. | $36M | Series A | Apr 27, 2023 |  |
| Therini Bio | Therini Bio is dedicated to the research and development of novel therapeutics for the treatment of neurological diseases. The company's approach is based on novel findings by the Akassoglou lab at Gladstone/UCSF that implicate fibrin as a key driver of neuroinflammation. | $17M | Seed | May 10, 2021 |  |

5 of 5 investments shown.

## Co-investors
- [Dolby Family Ventures](https://shizune.co/investors/profile/dolby-family-ventures) — VC Fund, 5 deals together
- [Dementia Discovery Fund](https://shizune.co/investors/profile/dementia-discovery) — VC Fund, 4 deals together
- [MRL Ventures Fund](https://shizune.co/investors/profile/mrl-venture-fund) — VC Fund, 4 deals together
- [Sanofi Ventures](https://shizune.co/investors/profile/sanofi-genzyme-bioventures) — VC Fund, 4 deals together
- SV Health Investors — VC Fund, 4 deals together
- [Alzheimer's Drug Discovery Foundation](https://shizune.co/investors/profile/alzheimers-drug-discovery-foundation) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Foundation for a Better World invest in?

Foundation for a Better World invests primarily in Health Care, Neuroscience and Biotechnology startups, most often at Series A and Seed stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Foundation for a Better World?

Public channels for Foundation for a Better World include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Foundation for a Better World?

The team at Foundation for a Better World includes Adam Hoffman (Executive). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co